Recurrent Thyroid Cancer Clinical Trial
Official title:
A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma
This phase II trial is studying how well tanespimycin works in treating patients with inoperable locoregionally advanced or metastatic thyroid cancer. Drugs used in chemotherapy, such as tanespimycin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
PRIMARY OBJECTIVES:
I. Determine the 1-year treatment failure rate in patients with inoperable locoregionally
advanced or metastatic medullary or differentiated thyroid carcinoma treated with
17-N-allylamino-17-demethoxygeldanamycin (17-AAG) (tanespimycin).
SECONDARY OBJECTIVES:
I. Determine the toxicity of this drug in these patients. Determine the 1-year
progression-free rate in patients treated with this drug.
II. Determine the response rate and duration of response in patients treated with this drug.
III. Determine the time to treatment failure and time to subsequent therapy in patients
treated with this drug.
IV. Determine the time to disease progression and overall survival of patients treated with
this drug.
V. Correlate the incidence rate of RAS, RAF, and RET mutations with clinical outcome in
patients treated with this drug.
OUTLINE: This is a multicenter study. Patients are stratified according to type of thyroid
carcinoma (medullary vs differentiated).
Patients receive tanespimycin intravenously (IV) over 2-6 hours on days 1, 4, 8, and 11.
Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 3 months until disease
progression and then every 6 months for up to 3 years from study entry.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02152137 -
Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
|
Phase 2 | |
Completed |
NCT00098813 -
Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
|
Phase 2 | |
Terminated |
NCT00095693 -
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
|
Phase 2 | |
Completed |
NCT00470496 -
Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer
|
Phase 1 | |
Active, not recruiting |
NCT01723202 -
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
|
Phase 2 | |
Completed |
NCT00085293 -
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
|
Phase 2 | |
Recruiting |
NCT04892303 -
Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer
|
Phase 1 | |
Terminated |
NCT00126568 -
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
|
Phase 2 | |
Completed |
NCT00519896 -
Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
|
Phase 2 | |
Completed |
NCT01502410 -
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
|
Phase 2 | |
Completed |
NCT01413113 -
Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery
|
Phase 1 | |
Completed |
NCT00134043 -
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
|
Phase 2 | |
Completed |
NCT00104871 -
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
|
Phase 2 | |
Completed |
NCT00068497 -
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
|
N/A | |
Completed |
NCT00004074 -
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
|
Phase 1 |